Structures of the lipids used in Figures 7-12. See Mankidy et al., 2010 for additional details.
Alzheimer’s disease (AD) is a complex cognitive disorder for which the single greatest risk factor is age. The pathophysiological basis for AD is still a matter of debate with no current hypothesis explaining all of the complex pathological changes observed. These include neurofibrillary tangles, amyloid plaques, neuroinflammation, hypomyelination, neuronal shrinkage (eg. N- basalis cholinergic neurons, resulting in a dramatic cholinergic deficit), ocular pathology, microvascular pathology and liver peroxisomal dysfunction. The hypothesis that we are presenting, namely peroxisomal dysfunction resulting in decreased supply of critical ethanolamine plasmalogens to the brain, eye and vascular endothelium, is the first hypothesis that can potentially explain all of these complex pathologies in AD. The value of this hypothesis is that it is imminently testable via resupply of critical ether lipid precursors of plasmalogens. PPI-1011 is such a drug candidate and will be presented after a review of the basis of this hypothesis.
2. Plasmalogens in aging and AD
Advancing age remains the largest risk factor for the development of AD. Pathologically, AD is primarily defined by the accumulation of amyloid plaques (AP) and neurofibrillary tangles (NFT), whereas clinically, AD is primarily defined as the progressive deterioration of mental function the earliest symptoms of which are reduced memory functions. Epidemiologically, these three features exhibit essentially superimposable age-severity plots [compare (Braak and Braak 1997) to (Bachman et al., 1992)], yet the mechanism behind this association remains elusive. In this section we attempt to peel back one more layer of the AD onion and put forward the hypothesis that age-related decline in the peripheral synthesis of ethanolamine plasmalogens (PlsEtn), a critical component of both neuronal membranes and myelin sheaths, is responsible for both the pathological and clinical AD cascade. The underlying cause behind peripheral PlsEtn depletion is currently unknown and therefore represents yet another layer to be uncovered in the future.
The time course of the presence and severity of the pathological features of AD was described in detail (Braak and Braak 1997) using a large population of non-selected post-mortem human brains (ages 26-95, n= 2661). In regards to amyloid deposition, they reported that initial amyloid patches appear in temporal areas such as the perirhinal and/or ectorhinal fields (Stage A) followed by spreading to adjoining neocortical areas and hippocampus (Stage B), and that the primary areas of the neocortex were the last regions to exhibit plaques (Stage C). Of the three stages, only the prevalence of stage C increases with age. This increase begins in the last half of the 6th decade of life. In regards to NFT, six stages are defined. The earliest signs are observed in the transentorhinal region (temporal lobe) (Stage I), then into the entorhinal region (Stage II), then to the hippocampus and temporal proneocortex (Stage III) then the adjoining proneocortex (Stage IV). The lesions then spread superolaterally (Stage V) and finally into the primary regions of the neocortex (Stage VI). In interpreting their data, Braak and Braak commented that the sequence of pathological progression is the inverse of the sequence of cortical myelination and that poorly myelinated areas were the first affected. This observation is of interest in that white matter, but not gray matter appears to exhibit an appreciable age-related degeneration as well (Meier-Ruge et al., 1992; Bartzokis, 2004). These findings have led some researchers to put forward the hypothesis that age-related myelin degeneration is a causative feature in AD (Bartzokis, 2004; Braak and Del Tredici, 2004). PlsEtn but not phosphatidylethanolamines (PtdEtn) exhibit an age-related decline after age 50-69 (Figure 1).
Interestingly, when the PlsEtn/PtdEtn pairs of the key white matter (18:1) and gray matter (22:6) PlsEtn are compared, the peak age of PlsEtn as a percentage of the ethanolamine phospholipid pool is 50-59. Docosahexaenoic acid (DHA, 22:6) shows the most precipitous decline with age (Figure 2). If PtdEtn and PlsEtn were co-regulated, these ratios should be constant with age. However, this is clearly not the case, indicating that selective plasmalogen decline occurs with age. This age effect is analogous to the above mentioned white matter depletion and AP/NFT accumulation. In addition, DHA-PlsEtn levels decrease in both post-mortem brain and pre-mortem serum samples with increasing Braak scale (Figure 3). These results are consistent with the dementia severity dependent decrease in DHA-PlsEtn in post-mortem brain previously reported (Han et al., 2001). A pharmacologically induced reduction of serum plasmalogens in healthy mice using cuprizone (a molecule that does not cross the blood-brain barrier), preferentially depletes DHA-PlsEtn in the serum and kidney but 18:1-PlsEtn in the CNS, the most abundant PlsEtn of myelin (Figure 4). These data support the hypothesis that a peripheral decline in PlsEtn can cause CNS PlsEtn depletion.
We have previously reported extensively on the role of plasmalogens in cognition and the association between serum DHA-PlsEtn levels and AD (Goodenowe et al., 2007; Wood et al., 2010). In brief, when compared to cognitively confirmed, age and gender-matched controls (MMSE 29-30, age 77+/-0.8, n=68), subjects with low (ADAS cog 5-19, age 79.3+/-0.8, n=78), moderate (ADAS cog 20-39, age 79.1+/-0.7, n=112), and severe (ADAS cog 40-70, age 82.1+/-1, n=66) dementia had increasingly lower levels of DHA-PlsEtn in their serum (74%, p=3.0e-4; 66%, p=1.3e-7; 53%, p=3.9e-11, respectively). This finding was confirmed in pre-mortem serum samples collected from subjects later confirmed pathologically to have AD and in Japanese subjects with mild AD (Goodenowe et al., 2007). Subsequently, the effect of serum DHA-PlsEtn levels at enrollment on the rate of cognitive decline over 12 months was investigated (Wood et al., 2010). It was observed that only subjects with serum DHA-PlsEtn of 75% or less of normal levels exhibited cognitive decline over a 12 month period. Using samples collected from Rush University’s Memory and Aging Program (Bennett et al., 2006) we investigated the predictability of pre-mortem MMSE scores (within 12 months of death) on post-mortem pathology (Figure 5).
These data indicate that pre-mortem MMSE scores of 25 or less are predictive of increased Braak stage and decreased DHA-PlsEtn levels, whereas MMSE scores of 20 or less are needed to be predictive of increased Aβ-42 (the key protein in amyloid plaques) levels. Further support for the role of DHA-PlsEtn in cognition is the observation that deficient liver biosynthesis of DHA correlates with cognitive impairment in AD (Astarita et al., 2010) and that phospholipid linked DHA (containing significant levels of plasmalogen) has a positive cognition effect whereas triglyceride linked DHA has a minimal effect (Hiratsuka et al., 2009).
The biosynthesis of DHA and plasmalogens occurs exclusively in peroxisomes (Nagan and Zoeller, 2001), however, it does not appear that the brain is a significant producer of these molecules. The key dietary metabolic precursor of DHA (alpha-linolenic acid) is converted to DHA in the liver, not the brain, and then transported to the brain pre-packaged on phospholipids. Peroxisomal function, as a whole, is known to decline with age (Munn et al., 2003; Mandel et al., 1998). Decreased peroxisomal function leads to decreased synthesis of PlsEtn and DHA (Zoeller and Raetz, 1986; Martinez, 1990). DHA synthesis involves chain elongation and desaturation of 18:3 n-3 fatty acids to 24:6 in the ER. The final step of DHA synthesis, β-oxidation to DHA, occurs in the peroxisome (Voss et al., 1991). Both DHAP synthase (Andre et al., 2006) and β-oxidase (Perichon and Bourre, 1995), exhibit decreased function with age and DHA containing PlsEtn are selectively decreased with age (Favreliere et al., 2000) In addition, the activity of catalase, the principal peroxisomal enzyme responsible for detoxifying H2O2 also decreases in activity with age (Perichon and Bourre, 1995; Favreliere et al., 2000; Rao et al., 1990), and is believed to be associated with increased lipid peroxidation with age. Accordingly, there is ample evidence of impaired plasmalogen synthesis and/or increased degradation with increasing age, however, the underlying causes and relative contribution of these processes are currently unknown.
3. Plasmalogen biochemistry and its role in AD
The fundamental role of PlsEtn is as a membrane lipid. PlsEtn constitute over 80 mol% of the ethanolamine phospholipid pool in non-neuronal brain membranes and over 60 mol% in neurons and synaptosomes (Han et al., 2001). PlsEtn found in white matter contain predominately 18:1, 20:1 and 22:4 fatty acids at the sn-2 position, whereas in gray matter, 22:6, 20:4, and 22:4 are found in highest concentration (Horrocks and Sharma, 1982). These differences result in dramatically different membrane structures. A high percentage of monounsaturates at
Abnormal cholesterol regulation has been extensively implicated in AD. One plausible theory that explains the sporadic accumulation of Aβ peptides in AD is a disruption in amyloid precursor protein (APP) processing due to increased membrane cholesterol levels (Puglielli et al., 2003). This theory is supported by evidence that membrane cholesterol increases with age in both rats and humans (Hegner, 1980) and that a high cholesterol diet can increase deposition of Aβ (Refolo et al., 2000) and Aβ accumulation is closely related to the processing of the cholesterol transport protein ApoE (Refolo et al., 2000; Pratico et al., 2001) Furthermore, membrane lipid analyses of post-mortem AD subjects have shown that AD severity is positively correlated with membrane cholesterol (Cutler et al., 2004).
PlsEtn deficient cells have been previously shown to have impaired HDL-mediated cholesterol efflux (Mandel et al., 1998) and impaired intracellular LDL-mediated transport (Munn et al., 2003). In both of these studies, normal functionality was restored by PlsEtn replacement (Munn et al., 2003). Using 1-O-alkyl, 2-acyl glycerols the peroxisomal biosynthesis of plasmalogens can be bypassed and specific classes of plasmalogens selectively enhanced or restored (Figure 6), (Mankidy et al., 2010) and the effect of such manipulations on cholesterol regulation investigated. In brief, we observed that plasmalogen deficient cells (N-Rel) had reduced levels of esterified cholesterol and increased levels of free and total cholesterol in the membrane (Figure 7). We further observed that selective restoration of polyunsaturated rather than saturated PlsEtns was more effective at increasing cholesterol esterification and lowering total and free cholesterol in plasmalogen deficient cells (Table 1, Figure 7).
This effect on cholesterol regulation was also observed in plasmalogen normal, HEK293 cells (Figure 8). The observed increase in cholesterol esterification was further determined to be due to increased levels of sterol-O-acetyltransferase (SOAT) and that this increase was not cholesterol related (no effect of escalating pravastatin dose; Figure 9). These observations explain the increase in esterified cholesterol and an elevated rate of HDL-mediated cholesterol efflux reported by others (Munn et al., 2003; Mandel al., 1998). These effects could not be reproduced by either PPAR agonists or by HMG-CoA reductase antagonists. Clearly membrane PlsEtn composition is a key determiner of cholesterol regulation.
The role of membrane composition on amyloid precursor protein (APP) processing has also been a topic of vigorous experimentation (Puglielli et al., 2003; Chauhan, 2003). The focus of these studies has been on the role of membrane cholesterol. In brief, APP when processed via the β-secretase pathway leads to the pathological accumulation of Aβ peptides. However, under normal conditions, less than 5% of APP is processed via this pathway. The vast majority of APP is processed via the non-pathological α-secretase pathway. Alpha-secretase is located in a phospholipid-rich membrane domain, whereas β-secretase is located in cholesterol-rich lipid rafts. Both of these enzymes are sensitive to changes in membrane cholesterol. When membrane cholesterol is increased, α-secretase activity is decreased (Kojro et al., 2001) and β-secretase activity is increased (Cordy et al., 2003). A similar set of experiments as that described above for cholesterol processing was carried out focusing on APP processing. Consistent with previously published findings, cholesterol loaded HEK293 cells exhibited increased AB42 secretion which was blocked by pravastatin treatment (Figure 10). Interestingly, C1 was observed to dose dependently decrease AB42 secretion. When the proteins involved in APP processing were investigated, it was observed that cholesterol elevated β-secretase levels, but had no effect on α-secretase. C1, on the other hand dose-dependently increased α-secretase levels and decreased β-secretase levels only at the high dose. Levels of sAPPα correlated with α-secretase levels. The effect of C1 versus pravistatin on α-secretase levels was further investigated in HEK293 cells under normal conditions (Figure 11) and it was observed that only C1 was effective at modulating α-secretase levels. Clearly membrane PlsEtn composition is also a key determiner of APP processing.
In regards to cognition, the most consistent neurochemical observation in AD is decreased choline acetyltransferase (ChAT) activity in the neocortex and hippocampus (Bennett et al., 2006; Perry et al., 1978; Wilcock et al., 1982; DeKosky et al., 1992; Behl et al., 2006). Reductions in cortical ChAT activity, monitored by biopsy or in autopsy samples, correlate with the extent of intellectual impairment in AD patients. In addition, these cortical cholinergic deficits have been found in patients examined within a year of onset of symptoms and cholinesterase inhibitors which potentiate residual cholinergic transmission, slow the decline in executive memory functions in AD patients (Behl et al., 2006). Furthermore, the inhibition of postsynaptic acetyl-choline (ACh) activity can directly induce cognitive dysfunction in healthy humans (Etienne et al., 1986). Studies of ChAT levels in the N. basalis and cortex in the same autopsy samples have shown that in 50% of AD patients there is a marked loss of cortical ChAT with no reduction in N. basalis ChAT suggesting abnormal axonal transport in AD and that the neurodegeneration originated at the axon terminal, not in the cell body.
PlsEtn are unique among neuronal lipids in that they have a high propensity to form an inverse hexagonal phase which is the essential transitory phase for successful membrane fusion events (Horrocks and Sharma, 1982). Optimal vesicular fusion is very sensitive to the amount and type of PlsEtn content. Relatively small reductions in either the vinyl ether content and/or the polyunsaturated fatty acid content of vesicles dramatically reduces the number of successful membrane fusion events (Han and Gross, 1991; Lohner et al., 1991). Therefore, this mechanism alone is sufficient to explain the correlation between decreased membrane PlsEtn and the severity of cognitive dysfunction in AD. However, in regards to cholinergic neurons there is yet a second mechanism of importance and that is pre-synaptic ACh synthesis. When a cholinergic nerve terminal releases ACh into the synaptic cleft during a depolarization event, the released ACh is ultimately degraded to choline and acetate by acetylcholineesterase (AChE). This extracellular choline in the synaptic cleft is then rapidly re-absorbed into the presynaptic terminal by the choline high affinity transporter (CHT). The reabsorbed choline is preferentially utilized by ChAT to re-synthesize ACh, which is then transported into vesicles by an ACh transporter protein and stored for future depolarizing events. Brain slice studies have shown that as long as the CHT is functioning normally, the cholinergic terminal can maintain ACh release for extended periods of time by utilizing membrane stores of PtdCho and PtdEtn (Ulus et al., 1989) and by the extraction of choline from surrounding cells (Farber et al., 1996). This occurs even in the absence of exogenous choline. However, in the presence of the CHT inhibitor, HC-3, the ability to sustain release of ACh is dramatically reduced, even in the presence of exogenous supplied choline (Maire and Wurtman, 1985). These data indicate that the proper functioning of the CHT is essential for the sustained release of ACh from cholinergic neurons. Recently, Ferguson
In summary, a deficiency in polyunsaturated PlsEtn in the CNS would be expected to reduce non-pathogenic APP processing, impair membrane cholesterol clearance, reduce vesicular release of neurotransmitters, and selectively impair pre-synaptic ACh replenishment following a nerve impulse. Accordingly, a therapeutic strategy aimed at developing an orally bioavailable DHA-PlsEtn precursor warrants clinical investigation in AD.
4. Plasmalogen replacement therapy for Alzheimer’s disease
The goal of our research program was to design an orally bioavailable DHA-plasmalogen precursor drug that bypasses age- and disease-sensitive peroxisomal biosynthetic pathways for both plasmalogens and DHA, thereby effectively restoring and/or enhancing DHA-plasmalogen-dependent synaptic and membrane functions that are diminished in AD, and which correlate with both clinical and pathological features of AD.
Since brain plasmalogens are supplied by the liver and intestinal mucosa, we established a research program to design an orally bioavailable ether lipid precursor that would bypass the requirement for peroxisomes to generate the ether lipid linkage at sn-1 of the glycerol backbone. Additionally, the decreased ability of the AD liver to synthesize DHA, along with decreased circulating plasma levels of DHA in AD patients, prompted us to substitute DHA as the fatty acid at sn-2 of the glycerol backbone. A sn-3 substituent was required to stabilize the DHA substitution at sn-2. The requirements for this substitution were: 1) A substituent that did not hinder hydrolysis at sn-3 by gut lipases to provide the alkyl-acyl-glycerol to the gut mucosa for addition of phosphoethanolamine at sn-3; 2) The released sn-3 substituent should be non-toxic and preferably beneficial; 3) Stabilization of the drug product; 4) Ease of synthesis and low cost of goods. A number of candidates were examined and lipoic acid was found to meet all of these criteria, as embodied in the drug development candidate PPI-1011
4.1. PPI-1011: Chemistry
PPI-1011 is an ether lipid plasmalogen precursor possessing palmitic acid at sn-1 of the glycerol backbone; DHA at sn-2 and lipoic acid at sn-3. That lipoic acid at sn-3 was the best moiety for both stabilizing the drug during storage and for synthetic purity.
For the synthesis of PPI-1011, solketal 1 was alkylated using cetyl bromide under phase transfer conditions (TBAB / aq. NaOH) to furnish 2. Acidic hydrolysis of the ketal in 2 gave 1-cetyl glycerol 3 in good yield. The primary hydroxyl at sn-3 position was selectively protected as a TBS ether to give 4. DHA was activated as its acid chloride using oxalyl chloride and then treated with 4 under basic conditions to furnish 5. Desilyation of 5 using equimolar mixture of TBAF / acetic acid proceeded smoothly to give 6 as the major product. Initial efforts to carry out the esterification of 6 with R-lipoic acid
The scheme was further modified to decrease the number of steps and increase the overall yield of the product. The primary alcohol in diol 3 was coupled with R-Lipoic under EDC/DMAP conditions to give 6 as the major product. Bis lipoic acid product formed as the minor product was easily separated by column chromatography. Esterification of the sn-2 position in 6 with DHA was also carried out under EDC/DMAP conditions to give PPI-1011. This route is superior to the previous route in the following ways: i) Protection-deprotection steps are avoided ii) Compound 6 can directly be carried forward for Step 2 (purification can be attempted after step 2) iii) This route is economically viable, easily scalable and can serve as a general protocol for the synthesis of analogues.
4.2. PPI-1011: In vitro data
The deacylation of DHA (22:6) from the
Restoring normal plasmalogen levels in plasmalogen-deficient cells with PPI-1011 also has been demonstrated to have the functional benefit of restoring cholesterol efflux and reducing cellular cholesterol levels in N-Rel cells (Nagan and Zoeller, 2001) as previously reported with other ether lipid precursors (Mankidy et al., 2010).
4.3. PPI-1011: In vivo data
Oral dosing of rabbits (manuscript in preparation) with PPI-1011 in gelatin capsules demonstrated dose (10 to 200 mg/kg)- and time (0 to 48 hr)-dependent augmentation of DHA-containing plasmalogens with further increases in doses (500 and 1000 mg/kg) not further augmenting circulating plasmalogen levels. DHA was also released, via deacylases, with peak plasma DHA levels at 6 hours and maximal plasma levels at a dose of 500 mg/kg rather than 200 mg/kg as observed with plasmalogens. These data support once daily dosing of PPI-1011 and demonstrate that circulating plasmalogens are auto-regulated thereby limiting the potential for toxicity from excess levels.
Total RNA was isolated from approximately 2 µg of pulverized cortex tissue using the RNeasy Mini Kit (Qiagen) as per the manufacture’s protocol. RNA was quantified by optical density with the NanoVue spectrophotometer (GE Healthcare Life Sciences). Reverse transcription reactions were performed on 800ng RNA using the qScript cDNA SuperMix (Quanta Biosciences). Each cortex samples was analyzed to determine expression of reelin (sense 5’-cccagcccagacagacagtt-3’; antisense 5’-ccaggtgatgccattgttga-3’), as well as the myelin markers myelin basic protein (sense-5' cctcaaagacaggccctcag 3'; antisense-5' cctgtcaccgctaaagaagc 3') and 2',3'-cyclic-nucleotide 3'-phosphodiesterase (EC 22.214.171.124; sense-5' catcctcaggagcaaaggag 3'; antisense-5' tgaatagcgtcttgcactcg 3') and the housekeeping gene β-actin (sense-5' agccatgtacgtagccatcc 3'; antisense-5' ctctcagctgtggtggtgaa 3' (Mack et al., 2007; Heinrich et al., 2006). Specificity of each primer set was determined by analysis of the dissociation curve. Quantitative real-time PCR was carried out in triplicate using the Fast SYBR Green Master Mix (Applied Biosystems) on the StepOne Plus Real-Time PCR System (Applied Biosystems). Thermocycling conditions were: 95°C for 20s followed by 40 cycles of 95°C for 3s and 60°C for 30s. For plasmalogen analyses, 10 mg of tissue powder in 5 mL screw cap tubes were polytroned in 1 mL of PBS + 0.5 mL MeOH. In the case of plasma, 100 L were vortexed with 1 mL of PBS + 0.5 mL MeOH. Next, 2 mL tert-butylmethylether were added to the plasma samples and tissue homogenates and the samples capped and shaken (1400 rpm) for 15 min at room temperature. The samples were then centrifuged for 8 min in a clinical centrifuge and 1 ml of the upper organic layer isolated for LC-MS/MS analyses of DHA, ethanolamine plasmalogens and phosphatidylethanolamines as reported previously (Wood et al., 2010). For cholesterol and myoinositol analyses, 2 mg of tissue powder in 5 ml screw cap tubes were polytroned in 1.2 ml of acetonitrile:MeOH:formic acid (800:200:2.4) containing [2H7]cholesterol and [2H6]myoinositol (Cambridge and CDN Isotopes) as internal standards. The homogenates were transferred to 1.5 ml screw top microtubes and centrifuged at 4°C and 25,000xg for 30 min. Next, 200 L of the supernatant were dried in a Savant centrifugal evaporator. Trimethylsilylation of the samples was conducted at 80°C for 1 hr with 100 L acetonitrile and 100 L of N,O-bis(trimethylsilyl)trifluoro-acetamide and TMCS (10/1). The TMS derivatives were analyzed by GC-MS with the [M-72]+ cations 386.3 and 393.3 monitored under ammonia PCI for cholesterol and [2H7]cholesterol, respectively and the [MH]+ cations of 613.2 and 619.2 monitored for myoinositol and [2H6]myoinositol, respectively.
Analysis of plasma phosphatidylethanolamines and ethanolamine plasmalogens revealed selective 20 to 40% decrements in free DHA and DHA containing phospholipids in cuprizone treated mice (Figure 15). Additionally, oral administration of PPI-1011 for 2 weeks fully restored these plasma decrements (Figure 15).
Cuprizone toxicity also resulted in significant decrements in kidney PlsEtns (Figure 16). PPI-1011 treatment restored kidney tissue levels of DHA-containing plasmalogens (PlsEtn 16:0/22:6, 18:0/22:6, 18:1/22:6) and augmented free DHA levels. PlsEtn18:1/18:2 was also restored with PPI-1011 treatment (Figure 16). In the cuprizone model, decrements in circulating and kidney DHA and DHA-containing plasmalogens are most likely the result of cuprizone toxicity in the liver (Heinrich et al., 2006). PPI-1011 clearly demonstrated oral bioavailability in that it was able to fully reverse these effects of cuprizone on circulating and kidney plasmalogens.
Analysis of neocortical ethanolamine phospholipids demonstrated selective and large reductions in white matter plasmalogens (PlsEtn). These included the 16:0/18:1 and 16:0/18:2 plasmalogens (Figure 17- B) as well as the 18:0/18:1, 18:0/18:2 PlsEtns (Figure 17-D). There were also significant reductions in the 18:0/18:1, 18:0/18:2 phosphatidylethanolamines (PtdEtn; Figure 17-C). With PlsEtn precursor treatment (PPI-1011), the decrements in the 16:0/18:2 (Figure 17-B) and 18:0/18:2 (Figure 17-D) PlsEtns and the 18:0/18:2 PtdEtns (Figure 17-C) were significantly reversed. PPI-1011 treatment also significantly augmented PtdEtn 16:0/18:2 in cuprizone treated mice (Figure 17-A). PPI-1011 did not alter PlsEtns with oleic acid (18:1) at sn-2 (Figure 17).
The marked ability of PPI-1011 to restore linoleic (18:2 at sn-2)-containing PlsEtn and phosphatidylethanolamines in both kidney and neocortex, suggests that PPI-1011 stimulates/induces a reacylation mechanism that favors 18:2 addition at sn-2.
To evaluate the potential benefits of plasmalogen replacement on myelin function, we examined the established myelin markers cholesterol, myo-inositol, myelin basic protein mRNA and 2',3'-cyclic-nucleotide 3'-phosphodiesterase mRNA. These markers were all reduced by 20 to 40% with 7 weeks of cuprizone treatment (Figure 18) and were significantly reversed by treatment with PPI-1011 for weeks 6 and 7 (Figure 18). PPI-1011 also induced reelin expression, an extracellular matrix glycoprotein involved in nerve regeneration (Figure 18). These increases in neocortical cholesterol, myo-inositol, myelin basic protein and 2',3'-cyclic-nucleotide 3'-phosphodiesterase and reelin (May et al., 2005) suggest that plasmalogen restoration may stimulate remyelination. Since cholesterol transport is dependent upon plasmalogens (Munn et al., 2003), PPI-1011 replenishment of plasmalogens may also contribute to restoration of cholesterol levels.
These data are relevant to AD in that AD pathology involves extensive hypomyelination as demonstrated by dramatic decrements in a number of myelin markers including plasmalogens (Han et al., 2001) sulfatides (Han et al., 2002); myelin basic protein (Wang et al., 2004) and 2',3'-cyclic nucleotide-3'-phosphodiesterase (Vlkolinsky et al., 2001), in autopsy studies of AD neocortex. Imaging studies also suggest that this process occurs in mild cognitive impairment (MCI) patients, consistent with the observations that myelin plasmalogens decrease early in the disease process (Han et al., 2001). Decrements in myelin and neuronal plasmalogens may well be responsible for the shrinkage in AD neurons that precedes final neuronal cell death (Scott et al., 1992; Stark et al., 2005; Vogels et al., 1990; Artaco-Perula and Insausti, 2007; Vereecken et al., 1994). Our data support previous studies indicating that myelin basic protein mRNA, 2',3'-cyclic-nucleotide 3'-phosphodiesterase mRNA, and plasmalogens with oleic acid and linoleic acid at sn-2 are reliable markers of myelin loss.
Our data for the first time also demonstrate that myelin decrements are reflected by decreases in neocortical phosphatidylethanolamines with oleic acid and linoleic acid at sn-2. With regard to therapeutic implications, these data indicate that plasmalogen precursors have the potential to correct brain plasmalogen and phosphatidylethanolamines deficits in leukodystrophies, multiple sclerosis and Alzheimer’s disease.
4.4. PPI-1011: Safety
While PPI-1011 is not an endogenous molecule, it is rapidly cleaved in the gut to yield two endogenous molecules, an alkyl-acyl-glycerol and lipoic acid. Previous human experience indicates that 1-o-octadecyl-sn-glycerol is consumed in the diet up to 100 mg/day and that supplementation with this ether lipid (5 to 10 mg/kg/day for 2 to 4 years) was not associated with any toxicity in children with peroxisomal disorders (Das et al., 1992)
AD patients treated with 1.72 g DHA/day for 12 months also have demonstrated no toxicity. Gastrointestinal side effects resulted in several drop-outs (Freund-Levi et al., 2008; Kotani et al., 2006); and 3) AD patients have been dosed with 600 mg of lipoic acid daily for 48 month with no toxicity (Maczurek et al., 2008). Lipoic acid (600 mg) also is an approved therapy for treating diabetic neuropathy, in Germany. These data suggest that PPI-1011 is a safe plasmalogen precursor that should restore neuronal membrane function. This should result in enhanced cholinergic transmission and improve the ADAS-cog scores of AD patients at least as well as a cholinesterase inhibitor. Furthermore, restoring membrane function should halt amyloid deposition and other ongoing pathological processes. PPI-1011 has the potential to be a first-in-class disease-modifying agent for AD.
4.5. PPI-1011: Formulation and stability
PPI-1011 is unstable as an oil but is stable in organic solvents (eg. dichloromethane) and in Neobee. The main impurity is the sulfoxide form of lipoic acid at sn-3. This impurity appears to be minimized by addition of the antioxidant thioglycerol to the formulation. We currently have 14 months of accelerated stability on this formulation.
In summary, our data support previous histochemical and biochemical studies demonstrating decrements in markers of neocortical myelin in the cuprizone mouse model (Skripuletz et al., 2008). However, ours is the first data to show that an orally administered plasmalogen precursor is capable of restoring some of these plasmalogens in the brain and that this can also result in remyelination as indicated by increases in cholesterol, myoinositol, myelin basic protein and 2',3'-cyclic nucleotide-3'-phosphodiesterase. Our data suggest that orally bioavailable plasmalogen precursors may offer a new therapeutic approach for neurodegenerative disorders. It has long been known that peripheral sources of DHA lipids are critical for brain and retinal function (Scott and Bazan, 2007). The importance of these observations has been highlighted by recent reports of decreased liver synthesis (Astarita et al., 2010) and circulating levels (Goodenowe et al., 2007) of DHA and DHA phospholipids in Alzheimer’s disease, which correlate with cognitive decline and brain decrements in DHA-containing plasmalogens (Han et al., 2001; Goodenowe et al., 2007; Wood et al., 2010). Clearly a next step is to define the site or sites of phospholipid remodeling that allow restoration of myelin plasmalogens and phosphatidylethanolamines. Labeled PPI-1011 is hoped to answer some of these questions. However, there are multiple anatomical sites and multiple enzymes that may participate in phospholipid remodeling processes. The gut, liver, brain and associated endothelial cell populations are all rich in remodeling enzymes. These include: i) the 1-acyl hydrolases, phospholipase A1 (EC 126.96.36.199), lysophospholipase (EC 188.8.131.52), acylglycerol lipase (EC 184.108.40.206); lipoprotein lipase (EC 220.127.116.11) and triacylglycerol lipase (EC 18.104.22.168); ii) the 2-acyl hydolases, phospholipase A2 (EC 22.214.171.124) and acylglycerol lipase (EC 126.96.36.199); iii) the 1-alkenyl hydrolase, alkenylglycerophosphoethanolamine hydrolase (EC 188.8.131.52); iv) the phosphethanolamine hydrolase, phospholipase C (EC 184.108.40.206); and v) the 2-acyltransferases, acylglycerophosphcholine o-acyltransferase (EC 220.127.116.11) and acyl Co-A:lyso-phosphatidylethanolamine acyltransferase (LPEAT2) (Cao et al., 2008). It remains to be defined if these remodeling enzymes can augment plasmalogens with oleic acid (18:1) at sn-2, after longer term dosing with PPI-1011.
We thank Dr. D.A. Bennett from the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, for the human brain samples collected with support from National Institute on Aging grant R01AG17917.
Andre, A., Juaneda, P., Sebedio, J.L. and Chardigny, J.M.: Plasmalogen metabolism-related enzymes in rat brain during aging: influence of n-3 fatty acid intake.Biochimie 2006
Anal. Quant. Cytol. Histol. Artacho-Pérula E. Insausti R. Quantitative estimations. of the. entorhinal cortex. in Alzheimer’s. disease 2007
PLoS One. Astarita G. Jung K. M. Berchtold N. C. Nguyen V. Q. Gillen D. L. Head E. Cotman C. W. Piomelli D. Deficient liver. biosynthesis of. docosahexaenoic acid. correlates with. cognitive impairment. in Alzheimer’s. disease P. Lo 2010e12538.
Neurology Bachman D. L. Wolf P. A. Linn R. Knoefel J. E. Cobb J. Belanger A. D’Agostino R. B. White L. R. Prevalence of. dementia probable senile. dementia of. the Alzheimer. type in. the Framingham. study 1992
Bartzokis, G.: Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease.J. Neurobiol. Aging 2004
Curr. Alzheimer Res. Behl P. Lanctot K. L. Streiner D. L. Guimont I. Black S. E. Cholinesterase inhibitors. slow decline. in executive. functions rather. than memory. in Alzheimer’s. disease a. 1-year observational. study in. the Sunnybrook. dementia cohort. 2006
Neurology Bennett D. A. Schneider J. A. Arvanitakis Z. Kelly J. F. Aggarwal N. T. Shah R. C. Wilson R. S. Neuropathology of. older persons. without cognitive. impairment from. two community-based. studies 2006
J. Neurobiol. Aging Braak H. Braak E. Frequency stages of. Alzheimer-related lesions. in different. age categories. 1997
J. Neurobiol. Aging. Braak H. Del Tredici K. Poor protracted myelination. as contributory a. factor to. neurodegenerative disorders. 2004
Biol. Chem. Cao J. Shan D. Revett T. Li D. Wu L. Liu W. Tobin J. F. Gimeno R. E. Molecular identification. of a. novel mammalian. brain isoform. of-Co acyl. A:lysophospholipid acyltransferase. with prominent. ethanolamine lysophospholipid. acylating activity. L. P. E. A. T. 2008
Chauhan N. B. Membrane dynamics. cholesterol homeostasis. Alzheimer’s disease. J. Lipid Res. 2003
Cordy, J.M., Hussain, I., Dingwall, C., Hooper, N.M. and Turner, A.J.: Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein.Proc. Nat. Acad. Sci. U.S.A. 2003
Proc. Nat. Acad. Sci. U.S.A. Cutler R. G. Kelly J. Storie K. Pedersen W. A. Tammara A. Hatanpaa K. Troncoso J. C. Mattson M. P. Involvement of. oxidative stress-induced. abnormalities in. ceramide cholesterol metabolism. in brain. aging Alzheimer’s disease. 2004
Das, A.K., Holmes, R.D., Wilson, G.N. and Hajra, A.K.: Dietary ether lipid incorporation into tissue plasmalogens of humans and rodents.Lipids 1992
Intraventricular Bethanecol Study Group. Annals of neurology De Kosky S. T. Harbaugh R. E. Schmitt F. A. Bakay R. A. Chui H. C. Knopman D. S. Reeder T. M. Shetter A. G. Senter H. J. Markesbery W. R. Cortical biopsy. in Alzheimer’s. disease diagnostic. accuracy neurochemical neuropathological. cognitive correlations. 1992
Drachman, D.A: Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977
Etienne P. Robitaille Y. Wood P. Gauthier S. Nair N. P. Quirion R. Nucleus basalis. neuronal loss. neuritic plaques. choline acetyltransferase. activity in. advanced Alzheimer’s. disease 1986Neuroscience 19 1279 1291
Farber, S.A., Savci, V., Wei, A., Slack, B.E. and Wurtman, R.J.: Choline’s phosphorylation in rat striatal slices is regulated by the activity of cholinergic neurons.Brain Res. 1996
Neurobiol. Aging Favreliere S. Stadelmann-Ingrand S. Huguet F. De Javel D. Piriou A. Tallineau C. Durand G. Age-related changes. in ethanolamine. glycerophospholipid fatty. acid levels. in rat. frontal cortex. hippocampus 2000
Ferguson S. M. Savchenko V. Apparsundaram S. Zwick M. Wright J. Heilman C. J. Yi H. Levey A. I. Blakely R. D. Vesicular localization. activity-dependent trafficking. of presynaptic. choline transporters. 2003
Interv. Ferguson S. M. Blakely R. D. The choline. transporter resurfaces. new roles. for synaptic. vesicles? Mol. 2004
Int. J. Geriatr. Psychiatry. Freund-Levi Y. Basun H. Cederholm T. Faxén-Irving G. Garlind A. Grut M. Vedin I. Palmblad J. Wahlund L. O. Eriksdotter-Jönhagen M. Omega supplementation in. mild to. moderate Alzheimer’s. disease effects. on neuropsychiatric. symptoms 2008
Glaser, P.E. and Gross, R.W.: Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion.Biochemistry 1994
Biochemistry Glaser P. E. Gross R. W. Rapid plasmenylethanolamine-selective. fusion of. membrane bilayers. catalyzed by. an isoform. of glyceraldehyde- 3-phosphate. dehydrogenase discrimination. between glycolytic. fusogenic roles. of individual. isoforms 1995
J. Lipid Res. Goodenowe D. B. Cook L. L. Liu J. Lu Y. Jayasinghe D. A. Ahiahonu P. W. Heath D. Yamazaki Y. Flax J. Krenitsky K. F. Sparks D. L. Lerner A. Friedland R. P. Kudo T. Kamino K. Morihara T. Takeda M. Wood P. L. Peripheral ethanolamine. plasmalogen deficiency. a. logical causative. factor in. Alzheimer’s disease. dementia 2007
Neurology Guttman C. R. Jolesz F. A. Kikinis R. Killiany R. J. Moss M. B. Sandor T. Albert M. S. White matter. changes with. normal aging. 1998
Exp. Gerontol. Haining J. L. Legan J. S. Catalase turnover. in rat. liver as kidney a. function of. age 1973
Han, X.L. and Gross, R.W.: Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs.Biochemistry 1990
Han, X.L. and Gross R.W.: Proton nuclear magnetic resonance studies on the molecular dynamics of plasmenylcholine/cholesterol and phosphatidylcholine/cholesterol bilayers.Biochim. Biophys. Acta. 1991
Han, X., Holtzman, D.M. and McKeel, D.W.Jr: Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry.J. Neurochem. 2001
J. Neurochem. Han X. Holtzman D. M. Mc Keel D. W. Jr Kelley J. Morris J. C. Substantial sulfatide. deficiency ceramide elevation. in very. early Alzheimer’s. disease potential. role in. disease pathogenesis. 2002
Hegner, D.: Age-dependence of molecular and functional changes in biological membrane properties.Mech. Ageing Dev. 1980
J. Neurosci. Heinrich C. Nitta N. Flubacher A. Muller M. Fahrner A. Kirsch M. Freiman T. Suzuki F. Depaulis M. Frotscher M. Haas C. A. Reelin deficiency. displacement of. mature neurons. but not. neurogenesis underlie. the formation. of granule. cell dispersion. in the. epileptic hippocampus. 2006
J. Nutr. Sci. Vitaminol. Hiratsuka S. Koizumi K. Ooba T. Yokosgoshi H. Effects of. dietary docosahexaenoic. acid connecting. phospholipids on. the learning. ability fatty acid. composition of. the brain. 2009
Hoppel, C.L. and Tandler, B.: Biochemical effects of cuprizone on mouse liver and heart mitochondria.Biochem. Pharmacol. 1973
Phospholipids. Hawthorne, J.N. and Ansell, G.B., editors. Elsevier, Amsterdam. Horrocks L. A. Sharma M. Plasmalogens O-alkyl glycerophospholipids. 1982 1982 51 93
Proc. Nat. Acad. Sci. U.S.A. Kojro E. Gimpl G. Lammich S. Marz W. Fahrenholz F. Low cholesterol. stimulates the. nonamyloidogenic pathway. by its. effect on. the alpha-secretase. A. D. A. M. 1. 2001
Neurosci. Res. Kotani S. Sakaguchi E. Warashina S. Matsukawa N. Ishikura Y. Kiso Y. Sakakibara M. Yoshimoto T. Guo J. Yamashima T. Dietary supplementation. of arachidonic. docosahexaenoic acids. improves cognitive. dysfunction 2006
Biochim. Biophys. Acta Lohner K. Balgavy P. Hermetter A. Paltauf F. Laggner P. Stabilization of. non-bilayer structures. by the. etherlipid ethanolamine. plasmalogen 1991
Lohner, K.: Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Chem.Phys. Lipids 1996
Mol. Cell. Biol. Mack J. T. Beljanski V. Soulika A. M. Townsend D. M. Brown C. B. Davis W. Tew K. D. Skittish” “. Abca knockout. mice display. tremor hyperactivity. abnormal myelin. ultrastructure in. the central. nervous system. 2007
Maire J.C. : Effects of electrical stimulation and choline availability on the release and contents of acetylcholine and choline in superfused slices from rat striatum. J. Physiol. (Paris) Wurtman R.J. 1985
Adv. Drug Deliv. Rev. Maczurek A. Hager K. Kenklies M. Sharman M. Martins R. Engel J. Carlson D. A. Münch G. . Lipoic acid. as an anti-inflammatory. neuroprotective treatment. for Alzheimer’s. disease 2008
Biochem. Biophys. Res. Commun. Mandel H. Sharf R. Berant M. Wanders R. J. Vreken P. Aviram M. Plasmalogen phospholipids. are involved. in H. D. L-mediated cholesterol. efflux insights. from investigations. with plasmalogen-deficient. cells 1998
Lipids Health Dis. Mankidy R. Ahiahonu P. W. Ma H. Jayasinghe D. Ritchie S. A. Khan M. A. Su-Myat K. K. Wood P. L. Goodenowe D. B. Membrane plasmalogen. composition cellular cholesterol. regulation a. structure activity. study 2010
Martinez, M.: Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of delta 4 desaturation? Neurology 1990
Cell Mol Life Sci. May P. Herz J. Bock H. H. Molecular mechanisms. of lipoprotein. receptor signalling. 2005
Ann. N.Y. Acad. Sci. Meier-Ruge W. Ulrich J. Meier E. Age-related white. matter atrophy. in the. human brain. 1992
. J. Lipid Res. Munn N. J. Arnio E. Liu D. Zoeller R. A. Liscum L. Deficiency in. ethanolamine plasmalogen. leads to. altered cholesterol. transport 2003
Nagan, N., Hajara, A.K., Larkins, L.K., Lazarow, P., Perdue, P.E., Rizzo, W.B. and Zoeller, R.A.: Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocol.J.Biochem. 1998
Nagan N. Zoeller R. A. Plasmalogens biosynthesis. functions Prog. Lipid Res. 2001
Biochimie Perichon R. Bourre J. M. Peroxisomal beta-oxidation. activity catalase activity. during development. aging in. mouse liver. 1995
Perichon, R., Moser, A.B., Wallace, W.C., Cunningham, S.C., Roth, G.S. and Moser, H.W.: Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion.Biochem. Biophys. Res. Commun. 1998
Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. and Perry R.H.: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.Br. Med. J. 1978
Pratico, D., Uryu, K., Leight, S., Trojanoswki,J.Q. and Lee, V.M.: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001
Puglielli L. Tanzi R. E. Kovacs D. M. Alzheimer’s disease. the cholesterol. connection Nat. Neurosci 2003
Mech. Ageing Dev. Rao G. Xia E. Richardson A. Effect of. age on. the expression. of antioxidant. enzymes in. male Fischer. F3 rats 1990
Neurobiol. Dis. Refolo L. M. Malester B. La Francois J. Bryant-Thomas T. Wang R. Tint G. S. Sambamurti K. Duff K. Pappolla M. A. Hypercholesterolemia accelerates. the Alzheimer’s. amyloid pathology. in a. transgenic mouse. model 2000
Scott, B.L., and Bazan, N.G.: Membrane docosahexaenoate is supplied to the developing brain and retina by the liver.Proc. Natl. Acad. Sci. U.S.A. 1989
Ann. Neurol. Scott S. A. De Kosky S. T. Sparks D. L. Knox C. A. Scheff S. W. Amygdala cell. loss atrophy in. Alzheimer’s disease. 1992
Am. J. Pathol. Skripuletz T. Lindner M. Kotsiari A. Garde N. Fokuhl J. Linsmeier F. Trebst C. Stangel M. Cortical demyelination. is prominent. in the. murine cuprizone. model is strain-dependent. 2008
Curr. Alzheimer Res. Stark A. K. Pelvig D. P. Jørgensen A. M. Andersen B. B. Pakkenberg B. Measuring morphological. cellular changes. in Alzheimer’s. dementia a. review emphasizing. stereology 2005
Brain research Ulus I. H. Wurtman R. J. Mauron C. Blusztajn J. K. Choline increases. acetylcholine release. protects against. the stimulation-induced. decrease in. phosphatide levels. within membranes. of rat. corpus striatum. 1989
Vereecken, T.H., Vogels, O.J. and Nieuwenhuys, R.: Neuron loss and shrinkage in the amygdala in Alzheimer’s disease.Neurobiol. Aging. 1994
Neurobiol. Aging. Vlkolinský R. Cairns N. Fountoulakis M. Lubec G. Decreased brain. levels of. 2’,3’-cyclic nucleotide-3’-phosphodiesterase. in Down. syndrome Alzheimer’s disease. 2001
J. Biol. Chem. Voss A. Reinhart M. Sankarappa S. Sprecher H. The metabolism. of 7,10,13,16,19-docosapentaenoic. acid to. 4,7,10,13,16,19-docosahexaenoic acid. in rat. liver is. independent of. a. 4-desaturase 1991
Neurobiol. Aging. Vogels O. J. Broere C. A. ter Laak. H. J. ten Donkelaar. H. J. Nieuwenhuys R. Schulte B. P. Cell loss. shrinkage in. the nucleus. basalis Meynert. complex in. Alzheimer’s disease. 1990
Neurosci,Res. Wang D. S. Bennett D. A. Mufson E. J. Mattila P. Cochran E. Dickson D. W. Contribution of. changes in. ubiquitin myelin basic. protein to. age-related cognitive. decline Neurosci. 2004
Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. Wilcock G. K. Esiri M. M. Bowen D. M. Smith C. C. Alzheimer’s disease. 1982
J. Psychiatry Neurosci. Wood P. L. Mankidy R. Ritchie S. Heath D. Wood J. A. Flax J. Goodenowe D. B. Circulating plasmalogen. levels Alzheimer Disease. Assessment-Cognitive Scale. scores in. Alzheimer patients. 2010
Zoeller, R.A., and Raetz, C.R.: Isolation of animal cell mutants deficient in plasmalogen biosynthesis and peroxisome assembly.Proc. Natl. Acad. Sci. U.S.A. 1986